Mayne Pharma has come under a fair bit of selling pressure following further investigations into price fixing for some of their generic drugs. The company reported that impact on their earnings would be minimal and the share price recovered a little bit on the back of that, but at one point it was down 20%. We do not cover the stock formally, but did publish recently on IDT Australia, a smaller version of Mayne. IDT recently announced that they've met the pre-conditions to sell one of their non-core assets and will now focus purely on being a specialist generic drug manufacturer. Click below for our short video covering Mayne and IDT, as well as overviews on Nanosonics and Sirtex. (VIEW LINK)
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
No areas of expertise